Phase 1b trial of NG-350A, a CD40 agonist antibody expressing adenoviral vector, in combination with chemoradiotherapy (CRT), in patients with mismatch repair-proficient (pMMR) locally advanced rectal cancer (LARC): Initial results from the FORTRESS study

capecitabine - Generic mfg.

NG-350A - Akamis Bio

https://www.abstractsonline.com/pp8/#!/21436/presentation/12155

Eric D. Miller1; Pannaga Malalur1; Sonal S. Noticewala2; Arvind Dasari2; Sheela Rao3; Andry Santoso3; Maria Hawkins4; Douglas Brand4; Rui Ru Ji5; Korinna Pilz6; Oliver Rosen5

Mar 18, 2026